GSK to set up global vaccine center near FDA, NIH

Finding itself with nine sites across the US devoted to vaccines research and development after its mega swapping deal with Novartis, GlaxoSmithKline has decided to consolidate and create a global R&D center focused on those products in Maryland – the home of the FDA and the National Institutes of Health (NIH) and close to Washington, the seat of the US federal government.